NEWS & MEDIA

  • News

News

Home>NEWS & MEDIA>News

Daewoong Pharmaceutical, First in Korea to Obtain a Patent for CoQ10
Day : 2006-05-10



Daewoong Pharmaceutical, First in Korea to Obtain a Patent for CoQ10

On the 25th of April 2006, Daewoong Pharmaceutical became the first in Korea to obtain a patent for CoQ10. The patent recently obtained was for its CoQ10 substance and its manufacturing method. This has served as a momentum builder with which Daewoong can build upon and has demonstrated the excellence of Daewoong’ CoQ10 product in the highly competitive CoQ10 market.

Even before obtaining the patent, its unrivaled technology had already won recognition for its CoQ10 winning the Jang Young-Shil Award and Health and Welfare Minister’s Award in 2005 and was selected as a next generation world-class product. “Through more than two years of research, we succeeded in synthesizing CoQ10 in large quantities and obtained a patent for it for the first time in Korea,” said Dr. Choi Su Jin, the leader of CoQ10 development and director of Daewoong’s central research institute. “We will distinguish it from others as the only ingredients with a patent in Korea and strengthen its unrivaled position in CoQ10 markets at home and abroad.” She also added that an international patent application related to CoQ10 was in preparation.

Meanwhile, Daewoong Pharmaceutical added that it would accelerate the marketing and selling of its CoQ10, considering the recent acquisition of a patent on CoQ10 would be a good opportunity to introduce the excellent quality of its CoQ10 ingredients in Daewoong’s ‘Gemron-CoQ10’, Daewoong’s general nutritional antioxidant product to customers.

“The recent Gemron-CoQ10 advertisement where Dr. Choi Su Jin appeared as a model is getting good responses from pharmacists and customers,” said Kim Jin Young, the assistant director of brand marketing at Daewoong Pharmaceutical. “Along with the advertising campaign, we will develop various marketing activities such as publicity activities targeting pharmacists and customers simultaneously.”

Prev The Excellence of EGF Reported In an International SCI Journal
Next Daewoong Pharmaceutical Reports Phase IV Clinical Trials of Prostate Cancer Treatment Drug (GnRH Agonist) Luphere®
목록